Review Article
The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma
Table 4
Rituximab-based salvage therapy in rituximab-naïve relapsing/refractory DLBCLs.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Plus radiotherapy at bulky disease. *The choice of conditioning regimen depended on the patient’s age, the extent of previous therapy and the clinical trials active at the time of transplantation (see [30]). #See [39]. **Each patient was assessed as his or her own control. WHO: World Health Organization classification of NHL; R: rituximab; ICE: ifosfamide, carboplatin, and etoposide; DHAP: cisplatin, cytarabine, and dexamethasone; VIM: etoposide, ifosfamide, and methotrexate; BEAM: carmustine, etoposide, cytarabine, and melphalan; N.R.: not reported; N.S.: not significant. |